Tweets
In 2010 Colchicine fell under patent protection and price increased 16 fold, & out-of-pocket price increased 4.4-fold, colchicine use decreased 27%, while allopurinol, steroid & gout visits (ER, Rheum) increased. https://t.co/xyOxsnoM5z https://t.co/yoXehV0mPa
Dr. John Cush @RheumNow ( View Tweet )
10 minutes 9 seconds ago
CAR-T Therapy: EULAR 2026 Conference Recap
https://t.co/XALrMFReOe https://t.co/TK0ot8MZb6
Dr. John Cush @RheumNow ( View Tweet )
3 hours 39 minutes ago
Do we need Better Strategies to Prevent Osteoporotic Fractures?
In a recent JAMA Viewpoints article, Dr. Susan Ott addresses several controversies in preventing osteoporosis (OP) related fractures.
https://t.co/YpmyZGCsjz https://t.co/NUkJVcxBjc
Dr. John Cush @RheumNow ( View Tweet )
7 hours 9 minutes ago
Gout Cavalcade (7.10.2026)
Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.
https://t.co/I1zWdx9fzU https://t.co/EYQ3D9Z42t
Dr. John Cush @RheumNow ( View Tweet )
8 hours 39 minutes ago
While not a validated Dx tool for gout, AI retinal scanning of digital fundus photography was tested on 107730 pts & showed high ROC - f NIDDM 0.833, Gout 0.832, OP 0.787, HTN 0.740, hyperlipidemia 0.736 & thyroid Dz 0.699 https://t.co/1yrlR04z4g https://t.co/c04YtVVERY
Dr. John Cush @RheumNow ( View Tweet )
22 hours 39 minutes ago
RHEUMATOLOGIST SURVEY ON GOUT - In what percentage of your new Gout patients, do you do arthrocentesis and crystal ID? Answer here: https://t.co/jpebQev4VU
Dr. John Cush @RheumNow ( View Tweet )
23 hours 22 minutes ago
RZV (Shingrix) response in 76 immunosuppressed SSc & 304 controls (CG) recv two RZV doses. High seroconversion seen in SSc but signif lower than CG (92.6% vs 99.7%, P 0.001), w/ lower concentration but comparable CMI, lower AE (74% vs 86%) https://t.co/ALlnVEZIAt https://t.co/kYYy2JIo2J
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
20 yr. Tx trends in 6583 #SSc pts. 2005 to 2025 endothelin receptor antagonists & prostanoids/prostacyclins from 3% to 28%. CCB & PDE-5 inh stable. CTX shifted to mycophenolate, RTX, & nintedanib. Steriods decr from 50% to 18% https://t.co/nrm1Ov285f https://t.co/ftLn3bGH72
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Registration is now open!
Join Dr. Jack Cush as he moderates an expert discussion with Dr. Nicola Dalbeth, Dr. John Fitzgerald, and Dr. Sarah Tedeschi on the evolving role of imaging in gout.
Topics include:
🔹 Ultrasound
🔹 Dual-energy CT (DECT)
🔹 Crystal identification
🔹 https://t.co/iOOAAAEneX
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
True or False: Extreme weight loss methods such as bariatric surgery and ketogenic diets may trigger gouty attacks, unlike GLP-1 agonist-induced weight loss.
Test your RheumIQ in this week's quiz at https://t.co/8BuwihOvfE.
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
EMD Serono Announces FDA Breakthrough Therapy Designation for Enpatoran (TLR 7/8 inhibitors) for use in Cutaneous Lupus; based on the results from the Phase 2 WILLOW study https://t.co/TNM4whC0Qk https://t.co/70Cibg1gkW
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
FDA - a 120Year History Protecting Americans. Nice overview.
- Began 1906 (as Bureau of Chemistry) w/ Pure Food & Drugs Act
- 1930 changed to Food and Drug Administration
- 1938 Food, Drug, and Cosmetics Act
- 1960s denied thalidomide approval https://t.co/3Ey98M9sxw My https://t.co/JS36EfJ19k
Dr. John Cush @RheumNow ( View Tweet )
2 days ago


